Harpoon Therapeutics

Daiichi pays Merck $170M to form lung cancer T-cell engager pact

Merck has quickly recouped some of the costs of its Harpoon buyout, pulling in $170 million by incorporating the lead candidate into its Daiichi deal.

Nick Paul Taylor Aug 6, 2024 8:17am

Biopharma M&A more than doubled in Q1 compared to a year ago

Apr 18, 2024 9:46am

Merck inks $680M Harpoon buyout to challenge Amgen

Jan 8, 2024 8:41am

AbbVie drops Harpoon’s BCMA drug, ending dream of $200M payday

Sep 14, 2023 10:21am